| Aug 12 |
Savara GAAP EPS of -$0.12 misses by $0.01
|
| Aug 12 |
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 5 |
Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week
|
| Jun 30 |
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
|
| Jun 28 |
Savara prices ~$100M stock offering
|
| Jun 28 |
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
|
| Jun 26 |
Savara: Today's Data 'Win' Rouses Market All Too Briefly
|
| Jun 26 |
Savara surges after late-stage trial win for lead asset against rare lung disease
|
| Jun 26 |
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
| Jun 26 |
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
